samedan logo
 
 
 
spacer
home > ebr > autumn 2002 > biotech investor relations - weathering the storm
PUBLICATIONS
European Biopharmaceutical Review

Biotech Investor Relations - Weathering the Storm

"The drug sector is out of favour...we have had 12 profits warnings in the pharma sector since January 2001 compared with two between 1990 and 2000. This is the worst time ever for pharma and it has impacted the biotech sector." Are these really the worst market conditions yet? Many think they are and it is certainly true that 2002 has so far been a roller coaster ride for investors in the biotech industry. Can companies attract investor support despite the doom and gloom? What should companies be doing to maximise the value of their shares? The biotech sector is suffering from the excesses of 2000 when over US$37 billion (versus US$16 billion in 2001) was raised, as well as from the poor broad market conditions. The market malaise reflects an uncertain outlook for equities in general, especially for high growth/risk sectors such as early stage biotechnology and technology-related stocks.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Mary Clark, Managing Director of Life Sciences Consulting at Thomson Financial

Mary Clark is Managing Director, Life Sciences Consulting at Thomson Financial. She specialises in building proactive investor relations programmes for life sciences companies at all stages of development, ranging from pre-IPO initiatives to expanding the reach of established multinational corporations.
Prior to joining Thomson Financial, Mary was Global Director of Corporate Communications at BTG plc, where she had overall responsibility for its investor relations, PR and media functions.

spacer
Mary Clark
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Five methods for reducing pharmaceutical cargo theft

In North America, five percent of cargo thefts that occurred in 2020 were pharmaceutical products and 74 percent of all cargo theft occurred in transit, according to the BSI and TT Club Cargo Theft Report 2021. In the US and Canada, the biggest threat comes when containers or trailers are parked at insecure locations, as those were the most exploited vulnerabilities last year. Market dynamics also changed due to Covid-19, as demonstrated by the fact that the theft of stolen cargo in the form of medical supplies such as PPE, increased by more than 5,000 per cent in 2020, compared to 2019.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement